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Hepatocellular carcinoma (HCC) is currently the second 
cause of cancer-related death worldwide and its incidence 
has been estimated to increase of about 20% by 2020 (1).
These dramatic epidemiology features are responsible 
for the increasing interest in finding effective preventive 
and therapeutic strategies. In the last years many efforts 
have been put in the primary prevention of HCC and in 
the improvement of therapeutic options. It is therefore 
unsurprising that many hot topics have risen and are 
currently at the centre of an intense debate. 
When it comes to the primary prevention of HCC, 
interventions toward the most prevalent risk factors have 
to be considered. The development and the subsequent 
widespread availability of effective anti-hepatitis B virus 
(HBV) drugs and vaccination left hepatitis C virus (HCV) 
infection and non-alcoholic fatty liver disease (NAFLD) 
as the main causes of HCC with unmet needs. Until now, 
HCV infection has been the leading cause of liver cirrhosis 
and HCC in Western population (1). The advent of direct 
antiviral agents (DAAs) with high efficacy in achieving 
sustained virological response (SVR) is now expected to 
reduce the incidence of de novo HCC in patients with 
eradicated HCV infection. Unfortunately, after post-
marketing surveillance, an SVR following DAAs seemed to 
be associated with a higher occurrence of de novo HCC and 
recurrence after HCC treated with curative therapies (2,3). 
Also, post-DAAs HCC seemed to show aggressive features 
with limited possibilities of receiving curative treatments (2). 
So far, two large prospective studies have been performed 
to verify these concerning reports (4,5). The results of these 
studies do not confirm the initial reports, observing a not 
increased risk of HCC in patients who underwent curative 
treatments, including liver transplantation. Moreover, SVR, 
obtained either with DAAs or interferon, was the pivotal 
factor in reducing cancer risk (4). Other recent studies 
suggested that DAAs do not impact on tumor aggressiveness 
(instead improving the early post-operative outcome) (6) 
and that biannual ultrasonography screening for HCC is 
highly expensive and little effective in non-cirrhotic patients 
receiving DAAs (7). So, which results should we trust about 
DAAs and risk of HCC? Serio et al. provide an extensive 
review of the current literature in this Special Issue to 
update the readers of Translational Cancer Research. In any 
case, prospective studies with a long-term follow up will be 
pivotal in settling the existing doubts (8).
Associated with the obesity and diabetes epidemics, 
NAFLD is becoming the leading cause of chronic liver 
disease in Western countries. NAFLD is an attributable 
cause of HCC, even before the development of cirrhosis (9). 
Effective strategies for identification of high-risk patients 
are urgently needed and represent a second hot topic in 
HCC. In the absence of strong and established evidences, 
most international guidelines do not support a widespread 
screening in these patients (10). Innovative biomarkers 
could help both in understanding the elusive pathogenesis 
of NAFLD-related HCC and in selecting particularly high-
risk patients. 
Therapeutic options are another debated topic in HCC. 
The existence of multiple international guidelines reflects 
different proposed strategies, even if actual discordances 
are limited (11). Medical community has always strived 
for better defining the indications for surgical and loco-
regional approaches, but one of the hardest challenges 
of the last decade involved the complex field of advanced 
HCC. After the approval of sorafenib, a series of trials 
of systemic treatments failed. In the last two years, four 
new molecules have shown efficacy. Regorafenib (12), 
cabozantinib (13), and ramucirumab (14) were superior to 
placebo in patients failing sorafenib (with regorafenib tested 
only in patients who withdrawn sorafenib for progressive 
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disease, and ramucirumab effective only in patient with 
alfa-fetoprotein >400 ng/mL). Also, lenvatinib was found 
to be non-inferior to sorafenib as first line therapy (15). 
Immunotherapy trials are showing promising results as 
well (16), leading to an early registration of nivolumab by 
the US Food & Drug Administration. The updated scenario 
of post-sorafenib treatments has been thoroughly reviewed 
by Nenu et al. for the readers of this special issue (17). The 
hottest topic in this field regards the search for biomarkers. 
Further knowledge is in fact needed to clarify which 
patients will possibly benefit from the agents of different 
classes (tyrosine kinase inhibitors and immune checkpoint 
inhibitors), helping both in the daily clinical practice and in 
the design of the trials (18). New locoregional techniques for 
the control of locally advanced HCC have been also studied 
in the latest years. Selective internal radiation therapy, also 
called transarterial radioembolisation (TARE), is based on 
the use of microspheres containing radioactive substances, 
first of all yttrium-90 (19). Preliminary experience in 
patients with neoplastic portal vein invasion led to the 
creation of a number of clinical trials about TARE. 
Expectations were frustrated by the failed SARAH (20) 
and SIRVENIB (21) trials, which did not find a benefit of 
TARE compared to sorafenib both in per-protocol and 
intention-to-treat analyses. Even more hope was placed 
in the SORAMIC trial, which investigated whether the 
combination of TARE + sorafenib was superior to sorafenib 
alone. Unfortunately, the results of this trial have been 
presented at an international liver congress and were 
equally disappointing (22). The next years will be crucial 
to understand if highly debated elements in the design 
of the SARAH and SIRENIB trials may have influenced 
the outcome. These factors include the relatively low 
experience in the use of TARE of some recruiting centers or 
the possibility to include also patients with high burden of 
disease (for instance neoplastic invasion of the main portal 
trunk) which were less likely to receive an adequate and 
nontoxic radiation dose). 
In conclusion, last years have been characterized by an 
exponential increase in knowledge concerning the optimal 
clinical approach of patients at risk of or affected by HCC, 
but this liver tumor is still a serious global public health 




Conflicts of Interest: The authors have no conflicts of interest 
to declare.
References
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. 
CA Cancer J Clin 2008;58:71-96.
2. Tsai PC, Huang CF, Yu ML. Unexpected early tumor 
recurrence in patients with hepatitis C virus-related 
hepatocellular carcinoma undergoing interferon-free 
therapy: Issue of the interval between HCC treatment and 
antiviral therapy. J Hepatol 2017;66:464.
3. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence 
and recurrence of hepatocellular carcinoma in HCV-
related cirrhosis treated with direct-acting antivirals. J 
Hepatol 2016;65:727-33.
4. Nahon P, Bourcier V, Layese R, et al. Eradication of 
Hepatitis C Virus Infection in Patients With Cirrhosis 
Reduces Risk of Liver and Non-Liver Complications. 
Gastroenterology 2017;152:142-56.e2.
5. Calvaruso V, Cabibbo G, Cacciola I, et al. Incidence 
of Hepatocellular Carcinoma in Patients With HCV-
Associated Cirrhosis Treated With Direct-Acting Antiviral 
Agents. Gastroenterology 2018;155:411-21.e4.
6. Vitale A, Russo FP, Sposito C, et al. Pathological 
characteristics and early post-hepatic-resection outcome 
of patients with hepatocellular carcinoma occurred after 
hepatitis C treatment with new direct-acting antivirals: a 
multicenter cohort study. J Hepatol 2018;68:S15.
7. Zangneh HF, Wong WW, Sander B, et al. Cost-
effectiveness analysis of hepatocellular carcinoma screening 
in hepatitis C cirrhosis after sustained viral response. J 
Hepatol 2018;68:S34.
8. Serio I, Napoli L, Leoni S, Piscaglia F. Direct antiviral 
agents for HCV infection and hepatocellular carcinoma: 
facts and FADs. Transl Cancer Res 2019;8:S223-32.
9. Kim GA, Lee HC, Choe J, et al. Association between non-
alcoholic fatty liver disease and cancer incidence rate. J 
Hepatol 2017. [Epub ahead of print].
10. Leoni S, Tovoli F, Napoli L, et al. Current guidelines 
for the management of non-alcoholic fatty liver disease: 
A systematic review with comparative analysis. World J 
Gastroenterol 2018;24:3361-73.
11. Tovoli F, Negrini G, Bolondi L. Comparative analysis 
of current guidelines for the treatment of hepatocellular 
S218 Ielasi et al. Hot topics in HCC
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2019;8(Suppl 3):S216-S218 tcr.amegroups.com
carcinoma. Hepat Oncol 2016;3:119-36.
12. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with 
hepatocellular carcinoma who progressed on sorafenib 
treatment (RESORCE): a randomised, double-blind, 
placebo-controlled, phase 3 trial. Lancet 2017;389:56-66.
13. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib 
(C) versus placebo (P) in patients (pts) with advanced 
hepatocellular carcinoma (HCC) who have received 
prior sorafenib: results from the randomized phase III 
CELESTIAL trial. J Clin Oncol 2018;36:abstr 207.
14. Lilly Announces CYRAMZA® (ramucirumab) Phase 
3 REACH-2 Study in Second-Line Hepatocellular 




15. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib 
in first-line treatment of patients with unresectable 
hepatocellular carcinoma: a randomised phase 3 non-
inferiority trial. Lancet 2018;391:1163-73.
16. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab 
in patients with advanced hepatocellular carcinoma 
(CheckMate 040): an open-label, non-comparative, 
phase 1/2 dose escalation and expansion trial. Lancet 
2017;389:2492-502. 
17. Nenu I, Breaban I, Pascalau S, et al. The future is now: 
beyond first line systemic therapy in hepatocellular 
carcinoma. Transl Cancer Res 2019;8:S261-74.
18. Tovoli F, Lorenzo S, Barbera MA, et al. Postsorafenib 
systemic treatments for hepatocellular carcinoma: 
questions and opportunities after the regorafenib trial. 
Future Oncol 2017;13:1893-905. 
19. Sangro B, Bilbao JI, Boan J, et al. Radioembolization 
using 90Y-resin microspheres for patients with advanced 
hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 
2006;66:792-800.
20. Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety 
of selective internal radiotherapy with yttrium-90 resin 
microspheres compared with sorafenib in locally advanced 
and inoperable hepatocellular carcinoma (SARAH): an 
open-label randomised controlled phase 3 trial. Lancet 
Oncol 2017;18:1624-36.
21. Chow PK, Gandhi M, Tan SB, et al. SIRveNIB: Selective 
Internal Radiation Therapy Versus Sorafenib in Asia-
Pacific Patients With Hepatocellular Carcinoma. J Clin 
Oncol 2018;36:1913-21.
22. Ricke J, Sangro B, Amthauer H, et al. The impact of 
combining Selective Internal Radiation Therapy (SIRT) 
with sorafenib on overall survival in patients with advanced 
hepatocellular carcinoma: the SORAMIC trial palliative 
cohort. J Hepatol 2018;68:S102.
Cite this article as: Ielasi L, Goio E, Tovoli F. Hot topics in 
hepatocellular carcinoma. Transl Cancer Res 2019;8(Suppl 
3):S216-S218. doi: 10.21037/tcr.2018.08.01
